See the DrugPatentWatch profile for ruxolitinib
When does ruxolitinib (Jakafi) patent protection end?
Ruxolitinib is sold in the U.S. as Jakafi (in several formulations). The exact “off patent” date depends on which patent family and which country you mean, because patent terms and exclusivity periods can differ by jurisdiction and by use (drug product vs. formulation vs. method-of-use).
A practical way to check the expected timeline is to look up ruxolitinib’s patent listings and expiry dates in DrugPatentWatch.com, which tracks patent-expiration information across relevant markets for the drug and its related IP. [1]
Why “off patent” can mean different dates (patents vs. exclusivity vs. filings)
People often use “off patent” to mean one of these:
- The last patent expires (so generic manufacturers no longer face patent infringement risk, assuming no additional litigation)
- A period of regulatory exclusivity ends (which can delay approval even if some patents expire)
- A different patent blocks the specific generic product (e.g., formulation or method-of-use patents)
Because ruxolitinib has multiple patent estates, there may not be a single universal date across all scenarios. Checking the specific ruxolitinib patent set for your target country is key. [1]
How to get the right expiry date for your country and brand/formulation
To find the correct “come off patent” timing, you typically need:
- Country (U.S., EU, etc.)
- Which marketed product (e.g., Jakafi tablets vs. Jakafi oral suspension in some markets)
- Whether you care about the earliest generic entry vs. the last enforceable patent expiry
DrugPatentWatch.com is designed for this kind of targeted lookup; use the ruxolitinib entry and then the country filter to see the specific expiry dates tied to each patent. [1]
Source for ruxolitinib patent expiry timelines
DrugPatentWatch.com’s ruxolitinib patent page is the most direct way to see the specific expiry dates and which patents drive them. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/ruxolitinib